Green light for new €3bn Innovative Medicines Initiative
This article was originally published in Scrip
Executive Summary
The European Parliament has voted in favor of the second Innovative Medicines Initiative (IMI2), a €3bn public-private research partnership run jointly by the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is aimed at improving the process of drug development by supporting cooperation in R&D.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.